Emergent BioSolutions | EBS - Equity Capital And Reserves


Emergent BioSolutions reported $649.3M in Equity Capital and Reserves for its fiscal quarter ending in December of 2023.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Akebia Therapeutics USD 32.61M 8.98M Dec/2025
ALKERMES USD 1.82B 85.86M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amarin USD 459.28M 387K Dec/2025
ANI Pharmaceuticals USD 540.72M 34.91M Dec/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Coherus Biosciences USD 61.01M 26.76M Dec/2025
Emergent BioSolutions USD 649.3M 47.9M Dec/2023
Exelixis USD 2.16B 619K Dec/2025
Glaxosmithkline GBP 22.06B 360M Dec/2025
Heron Therapeutics USD 13.28M 1.6M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Ironwood Pharmaceuticals USD -264.16M 44M Sep/2025
Lexicon Pharmaceuticals USD 107.54M 12.62M Dec/2025
Lonza CHF 9.13B 513M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Moderna USD 8.65B 680M Dec/2025
Myriad Genetics USD 368M 4.8M Dec/2025
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Pacira USD 693.11M 34.1M Dec/2025
Pfizer USD 92.8B 4.11B Sep/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Sanofi EUR 71.71B 1.55B Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
United Therapeutics USD 7.1B 506M Dec/2025
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025
Xoma USD 87.94M 15.5M Sep/2025